Methodological approaches to developing and establishing the body of evidence on post-marketing chinese medicine safety

Chinese Journal of Integrative Medicine

Volumn 19, Issue 7, 2013, Pages 494-497

  Liao, Xing ^a   Robinson, Nicola ^b  

^a INSTITUTE OF CHINESE MATERIA MEDICA   (China)

^b LONDON SOUTH BANK UNIVERSITY   (United Kingdom)

Author keywords

Chinese medicine; evidence; expert opinion; observational study; post marketing medicine

Indexed keywords

CHINESE DRUG; KUDIEZI; UNCLASSIFIED DRUG;

ADVERSE DRUG REACTION; ARTICLE; CHINESE MEDICINE; CLINICAL EFFECTIVENESS; CLINICAL PRACTICE; DRUG EFFICACY; DRUG SAFETY; EVIDENCE BASED MEDICINE; HUMAN; POSTMARKETING SURVEILLANCE; PRIORITY JOURNAL; RANDOM SAMPLE; UNSPECIFIED SIDE EFFECT;

EVIDENCE-BASED MEDICINE; HUMANS; MEDICINE, CHINESE TRADITIONAL; PRODUCT SURVEILLANCE, POSTMARKETING;

EID: 84879907589     PISSN: 16720415     EISSN: 19930402     Source Type: Journal    
DOI: 10.1007/s11655-013-1502-y     Document Type: Article

References (16)

1. Claridge J, Fabian T. History and development of evidence based medicine. World J Surg 2005;29:547-553.
2. Sackett DL, Strauss SE, Richardson WS, Rosenberg W, Haynes RB. Evidence-based medicine: how to practice and teach EBM. 2nd ed. Edinburgh: Churchill Livingstone; 2000.
3. Sackett DL, Rosenberg WM, Gray JA, Haynes RB, Richardson WS. Evidence based medicine: what it is and what it isn't. BMJ 1996;312:71-72.
4. Evidence-Based Medicine Working Group. Evidence-based medicine. A new approach to teaching the practice of medicine. JAMA 1992;268:2420-2425.
5. "Evidence-based health care and systematic reviews". The Cochrane Collaboration. http://www.cochrane.org/about-us/evidence-based-health- care. Retrieved 4 January 2013.
6. "What is EBM?". CEBM - Centre for Evidence Based Medicine. http://www.cebm.net/?o=1014. Retrieved Retrieved 4 January 2013.
7. Tonelli MR. In defense of expert opinion. Acad Med 1999;74:1187-1192.
8. Rawlins M. De testimonio: on the evidence for decisions about the use of therapeutic interventions. Lancet 2008;372:2152-2161.
9. Li NY, Abbott KV, Rosen C, An G, Hebda PA, Vodovotz Y. Translational systems biology and voice pathophysiology. Laryngoscope 2010;120:511-515.
10. McNeil JJ, Piccenna L, Ronaldson K, Ioannides-Demos LL. The value of patient-centred registries in phase IV drug surveillance. Pharm Med 2010;24:281-288.
11. Wang H, Ye X, Gao Q, Wu C, Qian Y, Luo B, et al. Pharmacovigilance in traditional Chinese medicine safety surveillance. Pharmacoepidemiol Drug Safety (Chin) 2009;18:357-361.
12. Lu QL, Fang JJ. A survey of twenty years ADR caused by traditioonal Chinese medicine. Adverse Drug Reactions J (Chin) 2001;91:18-21.
13. Zhang LL. Research on marketing strategy of Tong Hua Die mai ling. Masters Thesis (Chin) 2007;F830:33.
14. Liao X, Shen H, Xie YM, Zhang W, Yang W, LU ZG. Literature review report on safety evaluation about Kudiezi injection. China J Chin Mate Med (Chin) 2012;18:2786-2788.
15. Zuo ZJ, Huang QM. A systematic review of Kudiezi Injection in the treatment of angina pectoris. China Med Herald (Chin) 2011;4:32-35,73.
16. Jiang YB, Chen KJ.Systematic evaluation on the effect of Diemaining Injection in treating acute cerebral infarction. Chin J Clin Rehabil (Chin) 2006;27:100-101.